How To Understand The Resurgence of Eugenics
By Sydney Perkowitz,
JStor Daily [cites CGS]
| 04. 05. 2017
In 1883, the English statistician and social scientist Francis Galton coined the word “eugenics” (“well-born,” from Greek). The term referred to his idea of selectively breeding people to enhance “desirable” and eliminate “undesirable” properties. Seen as following Darwin’s theory of evolution, in the 1920s and ’30s eugenics gained important backing in England and the United States. Scientists and physicians spoke and wrote in its support. It influenced U.S. immigration policy, and states like Virginia used it to justify the forcible sterilization of the intellectually disabled.
Today’s growing anti-immigrant and white nationalist movements are raising concerns about a return of this long discredited dogma. For instance, U.S. Congressman Steve King (R-Iowa) recently tweeted about a far-right movement in Europe, calling Western culture “superior” and saying, “We can’t restore our civilization with somebody else’s babies.” King hoped for “an America that’s just so homogenous that we look a lot the same.”
At the same time, we are seeing an advance in methods of manipulating human DNA that, though they present many benefits, could also be used to advance eugenic goals. This...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...